BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:BMY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/04	21 : 00	Business Wire	Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	NYSE:BMY	Bristol Myers Squibb Co
2024/06/04	19 : 59	Business Wire	Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	NYSE:BMY	Bristol Myers Squibb Co
2024/06/03	23 : 13	Business Wire	Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	NYSE:BMY	Bristol Myers Squibb Co
2024/06/03	21 : 00	Business Wire	Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/06/01	21 : 00	Business Wire	KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/05/31	00 : 51	Business Wire	U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	NYSE:BMY	Bristol Myers Squibb Co
2024/05/29	19 : 59	Business Wire	Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	NYSE:BMY	Bristol Myers Squibb Co
2024/05/24	06 : 05	Business Wire	Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	NYSE:BMY	Bristol Myers Squibb Co
2024/05/23	20 : 40	IH Market News	OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News	NYSE:BMY	Bristol Myers Squibb Co
2024/05/23	19 : 59	Business Wire	Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	NYSE:BMY	Bristol Myers Squibb Co
2024/05/22	19 : 59	Business Wire	Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries	NYSE:BMY	Bristol Myers Squibb Co
2024/05/22	16 : 30	PR Newswire (US)	NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb	NYSE:BMY	Bristol Myers Squibb Co
2024/05/22	16 : 30	PR Newswire (US)	NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb	NYSE:BMY	Bristol Myers Squibb Co
2024/05/21	21 : 45	Business Wire	Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign	NYSE:BMY	Bristol Myers Squibb Co
2024/05/21	19 : 59	Business Wire	Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	NYSE:BMY	Bristol Myers Squibb Co
2024/05/16	23 : 26	Business Wire	New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis	NYSE:BMY	Bristol Myers Squibb Co
2024/05/16	09 : 57	Business Wire	Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	NYSE:BMY	Bristol Myers Squibb Co
2024/05/13	20 : 16	IH Market News	Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More	NYSE:BMY	Bristol Myers Squibb Co
2024/05/11	05 : 30	Business Wire	Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	NYSE:BMY	Bristol Myers Squibb Co
2024/05/07	19 : 59	Business Wire	Bristol Myers Squibb to Participate in Upcoming Investor Conferences	NYSE:BMY	Bristol Myers Squibb Co
2024/05/06	19 : 59	Business Wire	U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	NYSE:BMY	Bristol Myers Squibb Co
2024/05/06	19 : 59	Business Wire	European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...	NYSE:BMY	Bristol Myers Squibb Co
2024/05/01	21 : 00	GlobeNewswire Inc.	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	NYSE:BMY	Bristol Myers Squibb Co
2024/04/29	19 : 00	PR Newswire (US)	Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	NYSE:BMY	Bristol Myers Squibb Co
2024/04/26	19 : 59	Business Wire	CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	NYSE:BMY	Bristol Myers Squibb Co
2024/04/25	20 : 53	IH Market News	U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast	NYSE:BMY	Bristol Myers Squibb Co
2024/04/25	19 : 59	Business Wire	Bristol Myers Squibb Reports First Quarter Financial Results for 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/04/23	20 : 25	IH Market News	Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News	NYSE:BMY	Bristol Myers Squibb Co
2024/04/22	19 : 59	Business Wire	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	NYSE:BMY	Bristol Myers Squibb Co
2024/04/22	19 : 59	Business Wire	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	NYSE:BMY	Bristol Myers Squibb Co